Estimate the disease-free survival and the overall survival rate at 2 years.

Observe patterns of failure in the first 2 years.

Assess the level of comorbidity burden on morbidity and efficacy.

Determine if blood markers prior to, during the course of treatment (between the second and the last dose of SBRT), and at the first follow-up after SBRT predict 2-year primary tumor control and predict for grade ≥ 2 treatment-related toxicities

OUTLINE:

This is a multicentre study.Patients receive 3 fractions of stereotactic body radiotherapy over 14 days. Patients with disease progression undergo surgical resection as salvage local therapy.After completion of study therapy, patients are followed every 3 months for 2 years, every 6 months for 3 years and then annually thereafter.